Yourgene Health plc
(“Yourgene” or the “Group” or the “Company”)
Notice of AGM, Change of Registered Address and Investor Presentation
Manchester, UK – 25 August 2022: Yourgene (AIM: YGEN), the international molecular diagnostics group, announces that the Notice of Annual General Meeting (“AGM”) and Form of Proxy will shortly be available on the Company’s website at: www.yourgene-health.com/investors/key-documents/shareholder-communications and are being posted to those shareholders who have opted out of electronic communications. The majority of Yourgene shareholders receive electronic communications as part of the Company’s ESG programme. Yourgene is writing to all remaining shareholders to ask them to do the same to reduce paper usage and support the Company on its ESG initiatives. Change of registered office Yourgene also announces that the Company’s registered office address has changed to: Skelton House, Lloyd Street North, Manchester Science Park, Manchester M15 6SH with immediate effect. Notice of AGM and Investor presentation The Company’s AGM will be held at 2:00pm (BST) on Tuesday 27 September 2022, and will be held as a hybrid meeting electronically, via the Investor Meet Company platform (“IMC”) and physically, at the Company’s new offices Skelton House, Lloyd Street North, Manchester Science Park, Manchester M15 6SH. The Company’s CEO, Lyn Rees, will also provide shareholders with a short presentation after the formal business of the AGM concludes and there will be an opportunity for investors to ask questions. Investors can sign up to IMC for free and add to meet Yourgene Health plc via: https://www.investormeetcompany.com/yourgene-health-plc/register-investor Shareholders taking part via the IMC platform will not be able to speak or vote on the AGM resolutions. Shareholders are therefore strongly encouraged to exercise their voting rights by completing and submitting a Form of Proxy. It is highly recommended that Shareholders submit their Form of Proxy as early as possible to ensure that their votes are counted at the AGM. Shareholders are strongly encouraged to appoint the Chairman as your proxy to ensure that each Shareholder’s vote will be counted in the event of restrictions on shareholders and proxies attending the AGM in person. If you wish to submit a proxy vote for this meeting, please submit your vote online at www.signalshares.com. For your vote to be valid please ensure that it is received by no later than 2:00pm (BST) on Friday 23 September 2022. Alternatively, should you wish to vote via the CREST system, please see the instructions in the Notice of Meeting. If you wish to attend the AGM in your capacity as a shareholder, please bring proof of shareholding or if shares are held through a nominee account, a letter of representation, to facilitate your entry to the Meeting. Any shareholder wishing to attend in person must register in advance by contacting the Company at yourgene@walbrookpr.com. Open Day As previously announced on 16 August 2022, the Company is hosting an Open Day, immediately after the AGM, at its new facilities at Manchester Science Park, on Tuesday 27 September 2022 from 3:00pm to 6:00pm (BST), welcoming shareholders, analysts and other interested stakeholders. All Open Day attendees must register through Walbrook PR to reserve a space. For more information and to register, please email yourgene@walbrookpr.com or telephone Walbrook PR on +44 (0)20 7933 8780.Yourgene Health plc Lyn Rees, Chief Executive Officer Barry Hextall, Chief Financial Officer Joanne Cross, Director of Marketing | Tel: +44 (0)161 669 8122 |
| Cairn Financial Advisers LLP (NOMAD) Liam Murray / James Caithie / Ludovico Lazzaretti | Tel: +44 (0)20 7213 0880 |
| Singer Capital Markets (Corporate Broker) Aubrey Powell / Tom Salvesen / George Tzimas | Tel: +44 (0)20 7496 3000 |
Walbrook PR Ltd (Media and Investor Relations) Lianne Applegarth / Alice Woodings | Tel: +44 (0)20 7933 8780 or yourgene@walbrookpr.com Mob: 07584 391 303 / 07407 804 654 |
About Yourgene Health
Yourgene Health is an international molecular diagnostics group which develops integrated genomic technologies and services enabling precision medicine. The group works in partnership with global leaders in DNA technology to advance diagnostic science. Yourgene primarily develops, manufactures, and commercialises simple and accurate molecular diagnostic solutions, for reproductive health, precision medicine and now infectious diseases. The Group’s flagship products include non-invasive prenatal tests (NIPT) for Down’s Syndrome and other genetic disorders, Cystic Fibrosis screening tests, invasive rapid aneuploidy tests, and a recent extension into the oncology space with DPYD genotyping. The Yourgene Genomic Services team works with healthcare professionals, researchers and pharmaceutical organisations to support and accelerate scientific advances in genomic medicine. The division’s specialist services guide decisions about abnormalities, hereditary risk and treatment in addition to providing novel insights in research and discovery. Accredited clinical services are provided in Oncology and Reproductive Health within the UK and worldwide. The team of scientific experts offer consultative services to help guide partners in selecting the right technology and approach for their applications. In August 2020, Yourgene acquired Coastal Genomics, Inc., a sample preparation technology company based in Vancouver, Canada, enabling the Company to extend its offering and IP portfolio in the DNA sample preparation sector. The acquisition increased Yourgene’s geographical penetration into the US and Canada, supplementing existing coverage in the UK, Europe, MEA and Asia. Yourgene Health is headquartered in Manchester, UK with offices in Taipei, Singapore, the US and Canada, and is listed on the London Stock Exchange’s AIM market under the ticker “YGEN”. For more information visit www.yourgene-health.com and follow us on twitter @Yourgene_Health.
